SCHEMBL19783244

SCHEMBL19783244

COc1c(O)ccc2occc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 5/20 0.55
CYP1A1 P04798 6/20 0.48
CYP1B1 Q16678 5/20 0.48
CYP1A2 P05177 2/20 0.48
ABCB1 P08183 1/20 0.47
CYP3A4 P08684 3/20 0.46
ADORA3 P0DMS8 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
TSHR P16473 2/20 0.46
CYP2C19 P33261 2/20 0.46
HSD17B10 Q99714 2/20 0.46
PGR P06401 1/20 0.46
CYP2A6 P11509 1/20 0.46
KCNA2 P16389 1/20 0.46
MAOA P21397 1/20 0.46
PTPN1 P18031 3/20 0.42
HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2046713 0.78 CYP1A1 (0.47) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL954825 0.77 CYP1A1 (0.48) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL29639598 0.75 CYP1A1 (0.60) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL2045384 0.74 CYP1A1 (0.63) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL9623295 0.74 ESR1 (0.55) CYP3A4KDM4EALDH1A1TSHRMAOA
SCHEMBL2269866 0.74 KDM4E (0.47) KCNA3CYP3A4KDM4EALDH1A1HSD17B10
SCHEMBL19782823 0.73 ADORA3 (0.49) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL9129946 0.72 KCNA3 (0.78) KCNA3CYP1A1CYP1B1CYP1A2ABCB1
SCHEMBL30105479 0.72 KCNA3 (1.00) KCNA3CYP1A1CYP1B1CYP1A2CYP3A4
SCHEMBL27033003 0.72 CA12 (0.52) KCNA3CYP1A1CYP1B1CYP1A2ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 KCNA3 1858/4885CYP1A1 196/4885CYP1B1 167/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 KCNA3 1859/4885CYP1A1 164/4885CYP1B1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.